Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLASH-CV
NCT07077395Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in vasomotor symptoms comparing elinzanetant with Placebo (2 arms). Primary endpoint: Brachial artery flow mediated dilation at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT07077395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077395.